MRI is increasingly utilized for the diagnosis of liver disease and focal liver lesions. While liver-targeted gadolinium-based contrast agents (GBCAs) have high efficacy, they are shadowed by safety concerns regarding tissue retention. We have developed a liver-targeted manganese alternative – Mn-EOB-PC2A – that uses a liver-targeted ethoxybenzyl modified macrocyclic pyclen diacetate platform. Relaxivity measurements for Mn-EOB-PC2A suggest comparable performance to the GBCA alternatives, and in vitro characterization suggests strong uptake in hepatocytes with minimal toxicity. MRI with Mn-EOB-PC2A demonstrated strong liver-specific enhancement at a clinically relevant dose, underscoring the potential for Mn-EOB-PC2A as an alternative to traditional liver-targeted Gd-based platforms.